Source link : https://www.newshealth.biz/health-news/promising-agent-significantly-improves-disability-in-gbs/
MONTREAL — An investigational targeted immunotherapy for Guillain-Barré syndrome (GBS) more than doubled improvement in disability after 8 weeks compared with placebo and showed sustained benefit at 26 weeks, new findings that investigators say mark the first GBS treatment advance in 40 years. The phase 3 study investigated ANX005, a fully humanized recombinant immunoglobulin (Ig) […]
Author : News Health
Publish date : 2024-06-27 19:15:56
Copyright for syndicated content belongs to the linked Source.
Categories